PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report - Report - MDSpire

PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report

  • By

  • Zixin Li

  • Xuezhou Pang

  • Zhongyao Wang

  • Jing Wen

  • Yanli Zhao

  • Daiyuan Ma

  • Jianquan Yang

  • May 8, 2026

  • 0 min

Share

Clinical Report: Management of a Large SMARCA4-Deficient Cervical Tumor

Overview

{'add': 'Specify components of the PRaG5.0 regimen.'}

Background

{'add': 'More details on prognosis and treatment challenges.'}

Data Highlights

{'format': 'Ensure table format is consistent.'}

Key Findings

{'add': 'Details about symptoms and treatment timeline.'}

Clinical Implications

{'add': 'Discuss limitations or risks of PRaG5.0.'}

Conclusion

{'add': 'Significance of findings in existing literature.'}

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Complete Response of a Giant Metastatic Neck Mass in Tonsillar Squamous Cell Carcinoma Achieved with Radiotherapy Combined with Immunotherapy: A Case Report
  2. the asco post, 2025 -- Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
  3. Investigation of Changes in Tumor Microenvironment in Rectal Cancer Patients with Partial Response to Neoadjuvant Chemoradiotherapy, 2024
  4. Clinical Research in Cardiology, 2023 -- Combination of Cadonilimab and Anlotinib Shows Promise in Treating Rare Cardiac Angiosarcoma with Multiple Metastases: A Case Study and Review of Existing Literature
  5. FDA, 2024 -- FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
  6. Clin. Exp. Obstet. Gynecol. 2025; 52(12): 45103
  7. Frontiers, 2022 -- PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
  8. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer | FDA
  9. Clin. Exp. Obstet. Gynecol. 2025; 52(12): 45103
  10. Frontiers | PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

Original Source(s)

PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report

  • by Zixin Li, Xuezhou Pang, Zhongyao Wang, Jing Wen, Yanli Zhao, Daiyuan Ma, Jianquan Yang

  • May 8, 2026

Related Content

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Case Report: Cytokeratin-positive interstitial reticulum cell tumor with HLA loss of heterozygosity

Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection